BioMarin Pharmaceutical
San Rafael, California, United States · Biotechnology, Genetics, Health Care
BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions.
Key facts
- Headquarters
- San Rafael, California, United States
- Employees
- 3,100
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (BMRN)
- Website
- www.biomarin.com
- Company page
Recent activity at BioMarin Pharmaceutical
- : BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease.
- : BioMarin Appoints Cara Bauer as Executive Vice President, Chief People Officer
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): On September 15, 2026, BioMarin Pharmaceutical Inc. announced its decision to discontinue the development of VOXZOGO for children with Noonan syndrome. This decision came after evaluating various factors including the feasibility of the study and the existing treatment landscape for the condition, but it was clarified that the choice was not related to any safety or efficacy concerns regarding VOXZOGO. This announcement is significant for stakeholders as it may impact future product development and investment strategies.
- : SEC 8-K (5.02): On September 10, 2026, BioMarin Pharmaceutical Inc. expanded its Board of Directors from ten to eleven members by appointing Robert Plenge, M.D., Ph.D. His appointment to the Board is effective immediately from the Appointment Date, and he will also serve on the Science and Technology Committee. As an independent non-employee director, Dr. Plenge will receive the standard compensation accorded to non-employee directors, including director fees and retainer fees for his committee role, as detailed in the Company's definitive proxy statement. This change reflects the company's strategy to bolster its board capabilities with expertise in science and technology.
- : SEC 8-K (8.01): On August 31, 2026, BioMarin Pharmaceutical Inc. completed a Share Purchase Agreement to acquire Alesta Therapeutics B.V., making Alesta a wholly owned subsidiary of BioMarin. The agreement involved multiple parties including holders of shares of Alesta, Anaheim SpinCo B.V., and Shareholder Representative Services LLC. The transaction marks a significant expansion for BioMarin into the biotech sector, enhancing its portfolio of therapies. The Purchase Agreement details are available in a previous filing dated August 18, 2026, which outlines the terms and conditions of the agreement.
- : BioMarin and Ascendis Pharma Enter Global Settlement and License Agreement
- : SEC 8-K (1.01): On August 30, 2026, BioMarin Pharmaceutical Inc. entered into a binding term sheet with Ascendis Pharma A/S to resolve all pending proceedings related to the BioMarin Patent Rights. Under the terms of the agreement, BioMarin grants Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to specific patents associated with the C-type natriuretic peptide products known as 'TransCon CNP', 'navepegritide', or 'Yuviwel'. This settlement aims to clarify and mitigate litigation risks surrounding BioMarin's intellectual property, potentially impacting its market position in the related therapeutic area. The strategic implications of this licensing agreement may enhance collaboration and innovation in the field of peptide-based therapies.
- : BioMarin to acquire Alesta Therapeutics for $275 million
- : SEC 8-K (1.01): On August 17, 2026, BioMarin Pharmaceutical Inc. entered into a Share Purchase Agreement with Alesta Therapeutics B.V. to acquire the company for a cash-free, debt-free payment structure. The upfront cash amount is set at $275 million, with an additional potential payment of $215 million contingent on achieving development milestones. The share purchase, aimed at enhancing BioMarin's portfolio in rare disease therapies, is expected to close in Q3 2026, subject to closure conditions including legal approvals and pre-closing asset transfers to Anaheim SpinCo B.V. Various representations and warranties are included to ensure proper dealings between the parties.
Leadership
- Claudia Varela, Senior Area Director Nothern Latam Region
- Cara Bauer, Chief People Officer
- James Sabry, EVP, Chief Business Officer
- Arpit Davé, Executive Vice President
- Greg Friberg, Chief Research and Development Officer
- Cristin Hubbard, Chief Commercial Officer
- Alexander Hardy, Chief Executive Officer
Verified email and direct lines for BioMarin Pharmaceutical’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
BioMarin Pharmaceutical files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
BioMarin Pharmaceutical in the news
- Our Origin Story - BioMarin Pharmaceutical (Jun 17, 2026)
- BioMarin Reports Second Quarter 2026 Financial and Operating Results - PR Newswire (Aug 06, 2026)
- BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline - PR Newswire (Aug 18, 2026)
- BioMarin Appoints Cara Bauer as Chief People Officer - PR Newswire (Oct 05, 2026)
- BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome - PR Newswire (Jul 27, 2026)
- BMRN News Today | Why did BioMarin Pharmaceutical stock go up today? - MarketBeat (Jun 21, 2018)
- BioMarin Reports Third Quarter 2026 Financial and Operating Results - PR Newswire (Nov 02, 2026)
- BioMarin to Participate in Upcoming Investor Conferences - PR Newswire (Nov 04, 2026)
Companies similar to BioMarin Pharmaceutical
- ShockWave Medical · Biotechnology, Health Care, Medical, Therapeutics
- Novocure · Biotechnology, Health Care, Medical, Therapeutics
- Cepheid · Biotechnology, Genetics, Health Care, Medical
- Alexion · Biotechnology, Health Care, Medical, Therapeutics
- Grail · Biotechnology, Genetics, Health Care, Medical
About BioMarin Pharmaceutical: questions and answers
What does BioMarin Pharmaceutical do?
BioMarin is a global biotechnology company founded in 1997, dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of genetic conditions.
Where is BioMarin Pharmaceutical headquartered?
BioMarin Pharmaceutical is headquartered in San Rafael, California, United States.
How many employees does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has about 3,100 employees.
Who leads BioMarin Pharmaceutical?
Arpit Davé is an Executive Vice President at BioMarin Pharmaceutical.
What is the latest news on BioMarin Pharmaceutical?
On Oct 29, 2026, BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease.
Is BioMarin Pharmaceutical a public company?
Yes. BioMarin Pharmaceutical is publicly traded under the ticker BMRN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy